for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Boston Scientific Corporation

BSX

Latest Trade

42.65USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

34.34

 - 

46.62

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Boston Scientific Sees Q4 Adjusted Earnings Per Share $0.42-$0.45

Jan 14 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC - EXPECTS TO EXCEED PREVIOUS OUTLOOK FOR FY 2019 GAAP EARNINGS PER SHARE OF $0.72-$0.75 .BOSTON SCIENTIFIC - EXPECTS TO EXCEED PREVIOUS OUTLOOK FOR Q4 GAAP EARNINGS PER SHARE OF $0.22-$0.25 .SEES Q4 ADJUSTED EARNINGS PER SHARE $0.42-$0.45.BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR 2019.Q4 PRELIMINARY SALES $2.9 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.93 BILLION.Q4 EARNINGS PER SHARE VIEW $0.44, REVENUE VIEW $2.93 BILLION -- REFINITIV IBES DATA.ESTIMATES THAT IT WILL EXCEED ITS PREVIOUSLY ISSUED GUIDANCE FOR EARNINGS PER SHARE OF $0.22 TO $0.25 FOR Q4.ESTIMATES IT WILL EXCEED ITS PREVIOUSLY ISSUED GUIDANCE FOR EARNINGS PER SHARE OF $0.72 TO $0.75 FOR FY 2019, ON A GAAP PER SHARE BASIS.BOSTON SCIENTIFIC - ESTIMATES ADJUSTED EARNINGS WILL BE WITHIN PREVIOUSLY ISSUED GUIDANCE RANGE OF $1.55 TO $1.58 PER SHARE FOR FULL YEAR 2019.ESTIMATES Q4 ADJUSTED EARNINGS, EXCLUDING CERTAIN CHARGES (CREDITS), WILL BE WITHIN ITS PREVIOUSLY ISSUED GUIDANCE.FY2019 EARNINGS PER SHARE VIEW $1.57, REVENUE VIEW $10.76 BILLION -- REFINITIV IBES DATA.GENERATED PRELIMINARY FY 2019 SALES OF ABOUT $10.74 BILLION.

Boston Scientific - On Dec. 5, Company Entered $700 Million Credit Agreement

Dec 5 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC - ON DEC 5, CO ENTERED INTO A $700 MILLION CREDIT AGREEMENT - SEC FILING.BOSTON SCIENTIFIC - CREDIT AGREEMENT PROVIDES FOR $700 MILLION 364 DAY TERM LOAN MATURING ON DEC 3, 2020.BOSTON SCIENTIFIC - PRINCIPAL AMOUNT OF 2019 TERM LOAN WILL BEAR INTEREST AT AN ANNUAL RATE OF LIBOR PLUS A MARGIN OF 0.65%.BOSTON SCIENTIFIC - TERM LOAN WILL BE USED TO REPAY REMAINING AMOUNTS OUTSTANDING UNDER 2-YEAR TRANCHE OF 2 TRANCHE $2 BILLION TERM LOAN CREDIT AGREEMENT.

Boston Scientific's Unit And Ontario Municipal Employees Retirement System Entered Into Royalty Purchase Agreement

Nov 26 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC CORP - ON NOV 26, UNIT OF CO AND ONTARIO MUNICIPAL EMPLOYEES RETIREMENT SYSTEM ENTERED INTO ROYALTY PURCHASE AGREEMENT.BOSTON SCIENTIFIC CORP - CO'S SUBSIDIARY SOLD TO OMERS 50% OF ROYALTIES PAYABLE IN RESPECT OF WORLDWIDE NET SALES OF ZYTIGA.BOSTON SCIENTIFIC CORP - PURCHASE PRICE FOR SUCH ROYALTY INTERESTS WAS U.S. $256 MILLION IN CASH.BOSTON SCIENTIFIC CORP - TRANSACTION IS EXPECTED TO HAVE NO IMPACT ON BOSTON SCIENTIFIC'S INCOME STATEMENT FOR 2019 AND THEREAFTER.BOSTON SCIENTIFIC CORP - CASH PROCEEDS FROM TRANSACTION ARE EXPECTED TO BE USED PRIMARILY TO PAY DOWN DEBT.BOSTON SCIENTIFIC CORP - TRANSACTION DOES NOT IMPACT BOSTON SCIENTIFIC'S FINANCIAL GUIDANCE FOR 2019 AS ROYALTY BUSINESS WAS DEEMED A PASSIVE BUSINESS.

Boston Scientific Prices €900 Mln Of Senior Notes

Nov 6 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC PRICES €900,000,000 OF SENIOR NOTES.BOSTON SCIENTIFIC CORP - PRICING OF OFFERING OF EUR 900 MILLION OF 0.625% NOTES DUE 2027.

Biocardia - Filed Counterclaim In Federal Action Against Boston Scientific Parties, Surbhi Sarna

Nov 6 (Reuters) - BioCardia Inc <BCDA.O>::BIOCARDIA - ON OCT 31, FILED COUNTERCLAIM IN FEDERAL ACTION AGAINST BOSTON SCIENTIFIC PARTIES, SURBHI SARNA.BIOCARDIA INC - SEEKS IMPOSITION OF CONSTRUCTIVE TRUSTS BOTH ON PATENTS NAMING SURBHI SARNA AS AN INVENTOR.BIOCARDIA INC - SEEKS PROCEEDS RECEIVED FROM SALE OF NVISION TO BOSTON SCIENTIFIC, DAMAGES, INCLUDING UNJUST ENRICHMENT DAMAGES MEASURED BY PROCEEDS.

Boston Scientific Reports Q3 GAAP Earnings Per Share Of $0.09

Oct 23 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2019.Q3 GAAP EARNINGS PER SHARE $0.09.Q3 SALES $2.707 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.65 BILLION.Q3 EARNINGS PER SHARE ESTIMATE $0.38 -- REFINITIV IBES DATA.SEES Q4 ADJUSTED EARNINGS PER SHARE $0.42 TO $0.45 EXCLUDING ITEMS.Q3 ADJUSTED EARNINGS PER SHARE $0.39.SEES REVENUE GROWTH FOR FULL YEAR 2019 TO BE IN A RANGE OF APPROXIMATELY 9 TO 9.5 PERCENT ON A REPORTED BASIS.SEES REVENUE GROWTH FOR FULL YEAR 2019 TO BE IN A RANGE OF APPROXIMATELY 7.5 PERCENT ON AN ORGANIC BASIS.BOSTON SCIENTIFIC - QTRLY CARDIOVASCULAR NET SALES $1,011 MILLION, UP 11.3%.SEES 2019 INCOME ON A GAAP BASIS IN A RANGE OF $0.72 TO $0.75 PER SHARE.SEES 2019 ADJUSTED EARNINGS IN A RANGE OF $1.55 TO $1.58 PER SHARE.Q4 EARNINGS PER SHARE VIEW $0.44 -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $1.56, REVENUE VIEW $10.70 BILLION -- REFINITIV IBES DATA.

Boston Scientific Announces FDA Approval Of Imageready Mri For Vercise Gevia Deep Brain Stimulation System

Aug 19 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC ANNOUNCES FDA APPROVAL OF IMAGEREADY™ MRI FOR VERCISE GEVIA™ DEEP BRAIN STIMULATION SYSTEM.BOSTON SCIENTIFIC - VERCISE GEVIA DEEP BRAIN STIMULATION SYSTEM, VERCISE CARTESIA DIRECTIONAL LEAD IS DESIGNED TO TREAT PARKINSON'S DISEASE SYMPTOMS.

Boston Scientific Says Submitted Borrowing Request For $2 Bln To Be Funded On Aug 19

Aug 19 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC - SUBMITTED BORROWING REQUEST FOR $2.0 BILLION TO BE FUNDED ON AUG 19.BOSTON SCIENTIFIC CORP - FUNDS FROM DRAWDOWN WILL BE USED TO PARTIALLY FINANCE BOSTON SCIENTIFIC'S ACQUISITION OF BTG PLC.BOSTON SCIENTIFIC - BORROWINGS UNDER TWO-YEAR DELAYED DRAW TERM LOAN CREDIT FACILITY WILL MATURE TWO YEARS FROM DATE OF CLOSING OF BTG ACQUISITION.BOSTON SCIENTIFIC - BORROWINGS UNDER THREE-YEAR DELAYED DRAW TERM LOAN CREDIT FACILITY WILL MATURE THREE YEARS FROM DATE OF CLOSING OF BTG ACQUISITION.BOSTON SCIENTIFIC - EXPECTS TO COMPLETE ANNOUNCED SALE OF GLOBAL EMBOLIC MICROSPHERES PORTFOLIO TO VARIAN MEDICAL SYSTEMS.

Boston Scientific Closes Acquisition Of BTG Plc

Aug 19 (Reuters) - BTG PLC <BTG.L>::BOSTON SCIENTIFIC CLOSES ACQUISITION OF BTG PLC.

BTG Says High Court Of Justice In England And Wales Sanctions Scheme On Boston Scientific Deal

Aug 15 (Reuters) - BTG Plc <BTG.L>::HIGH COURT OF JUSTICE IN ENGLAND AND WALES HAS TODAY MADE AN ORDER SANCTIONING SCHEME ON DEAL REGARDING BOSTON SCIENTIFIC.LAST DAY OF DEALING IN SHARES WILL BE 16 AUGUST 2019, ONCE SUSPENDED IT IS NOT EXPECTED THAT TRADING IN BTG SHARES WILL RECOMMENCE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up